Currently, combined therapeutic strategies, including the synergistic use of OCA and GLP-1 receptor agonists, which address mechanisms related to improving insulin resistance and inhibiting fibrosis progression, are in the preliminary stages of clinical trials [26,158]. The gene discussed is GLP1R; the disease is Insulin resistance.